The FDA gave therapy status to Proteostasis Therapeutics' PTI-428, which is being developed as a treatment for patients with cystic fibrosis who have two copies of the F508del genetic mutation and are currently receiving treatment with Vertex Pharmaceuticals' Orkambi, or lumacaftor/ivacaftor.
FDA breakthrough therapy status granted to Proteostasis' cystic fibrosis drug
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.